Founded by Pappas Ventures in 2005, CoLucid is a clinical stage biopharmaceutical company developing therapeutics to treat neurological dysfunctions. CoLucid's lead asset is lasmiditan, a potent and selective 5-HT1F receptor agonist licensed from Eli Lilly & Co. that has the potential to be useful in the acute treatment of migraine headaches. CoLucid’s lead asset, lasmiditan, has been shown to be safe and effective in Phase 2b trials.

CoLucid completed a successful IPO in 2015 and was acquired by Eli Lilly & Co. for nearly $1 billion in 2017.